ROCKLAND, Mass.--(BUSINESS WIRE)--Oct. 29, 2007--BioSphere Medical, Inc. (NASDAQ: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations, announced today that Richard Faleschini, President and Chief Executive Officer, is scheduled to present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7, 2007 at 10:30 am Eastern Time. The event is taking place at the New York Palace hotel.

The presentation will be broadcast live over the Internet via the "Investors" page of the BioSphere Medical website at www.biospheremed.com or at http://www.wsw.com/webcast/rrshq12/bsmd. To listen to the live event, go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available at the Company's website for 90 days following the presentation.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.

    CONTACT: BioSphere Medical, Inc.
             Martin Joyce, 781-681-7925
             Executive Vice President and Chief Financial Officer
             or
             Investor Relations:
             The Equity Group Inc.
             Devin Sullivan, 212-836-9608
             Senior Vice President

    SOURCE: BioSphere Medical, Inc.